Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
41 results about "FLT3 Inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Any drug or substance that inhibits the activity of receptor-type tyrosine-protein kinase FLT3 protein.
Methods for the treatment and management of myeloproliferative diseases using 4-(AMINO)-2-(2,6-dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
InactiveUS20090088410A1Reduce adverse effectsImprove toleranceBiocideAnimal repellantsJAK1 InhibitorMedicine
Methods of treating, preventing and / or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, in combination with a second active agent. Particular second active agents are is prednisone, JAK1 inhibitor, JAK2 inhibitor, FLT3 inhibitor, BCL2 inhibitor, and HDAC inhibitor.
Owner:CELGENE CORP
Phospho-specific antibodies to Flt3 and uses thereof
ActiveUS7183385B2Animal cellsImmunoglobulins against cell receptors/antigens/surface-determinantsTyrosinePhospho-Specific Antibodies
The invention discloses two newly-discovered Flt3 phosphorylation sites, tyrosine 589 (Tyr589) and tyrosine 591 (Tyr591) in the intracellular domain, and provides antibodies, both polyclonal and monoclonal, that selectively bind to Flt3 when phosphorylated at these novel sites. Also provided are assays utilizing these reagents, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibodies, that binds to Flt3 when phosphorylated at Tyr589 or Tyr591. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).
Owner:CELL SIGNALING TECHNOLOGY
Flt3 inhibitors for immune suppression
InactiveUS20090054358A1Suppressing response of cellReduce in quantityBiocideNervous disorderAcquired immunodeficiencySystemic lupus erythematosus
New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′: Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
Owner:JANSSEN PHARMA NV
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from compounds of Formula I′:Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.
Owner:JANSSEN PHARMA NV
Pteridine ketone derivative and applications thereof as egfr, blk, and flt3 inhibitor
ActiveUS20150126508A1Inhibit growthPrevent proliferationBiocideOrganic chemistryPteridine synthesisDisease
Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.
Owner:SHANGHAI YIDIAN PHARM TECH DEV CO LTD
Pteridinone derivative used as FLT3 inhibitor, and application thereof
ActiveCN107151249ANew structureStrong inhibitory activityOrganic active ingredientsSenses disorderPteridinonesMedicinal chemistry
Owner:EAST CHINA UNIV OF SCI & TECH
Use of pteridinone derivatives as FLT3 inhibitors
Owner:EAST CHINA UNIV OF SCI & TECH
Phospho-specific antibodies to flt3 (tyr969) and uses thereof
InactiveUS20100093008A1Microbiological testing/measurementDisease diagnosisPhosphoric acidPhospho-Specific Antibodies
The invention discloses a newly discovered Flt3 phosphorylation site, tyrosine 969 (Tyr969) in the intracellular domain, and provides reagents, including polyclonal and monoclonal antibodies, that selectively bind to Flt3 when phosphorylated at this site. Also provided are assays utilizing this reagent, including methods for determining the phosphorylation of Flt3 in a biological sample, selecting a patient suitable for Flt3 inhibitor therapy, profiling Flt3 activation in a test tissue, and identifying a compound that modulates phosphorylation of Flt3 in a test tissue, by using a detectable reagent, such as the disclosed antibody, that binds to Flt3 only when phosphorylated at Tyr969. The sample or test tissue may be taken from a subject suspected of having cancer, such as acute myelogenous leukemia (AML).
Owner:CELL SIGNALING TECHNOLOGY
Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof
ActiveUS9987278B2Organic active ingredientsMicrobiological testing/measurementAnticarcinogenFlt3 mutation
Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.
Owner:FUJIFILM CORP
Phenylacetamides being FLT3 inhibitors
Compounds of formulawherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.
Owner:NOVARTIS AG
Flt3 inhibitors for immune suppression
The invention refers to an FLT3 inhibitors for immune suppression. New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Pharmaceutical composition for treating FLT3 mutation-positive cancer, mutant FLT3 inhibitor and uses thereof
ActiveUS20170165262A1Organic active ingredientsMicrobiological testing/measurementAnticarcinogenCompound (substance)
Provided are a pharmaceutical composition for treating an FLT3 mutation-positive cancer; a mutant FLT3 inhibitor; and uses thereof. Disclosed are a pharmaceutical composition for treating an FLT3 mutation-positive cancer, containing a compound represented by General Formula [1] or a salt thereof as an active ingredient; a mutant FLT3 inhibitor; an anticancer agent; a method for predicting a therapeutic effect by administration of a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof in a subject, including a step of detecting the presence or absence of an FLT3 mutation; a method for selecting a subject to whom a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is applied, including a step of detecting the presence or absence of an FLT3 mutation; and a method for determining whether or not a pharmaceutical composition containing a compound represented by General Formula [1] or a salt thereof is administered to a subject, including a step of detecting the presence or absence of an FLT3 mutation.
Owner:FUJIFILM CORP
Phenylacetamides being FLT3 Inhibitors
Compounds of formulawherein the residues R1, R2, R3, R9, R10 and Q and X, Y and Z are as defined in the specification, salts thereof; their use, methods of their use, processes for their production, pharmaceutical compositions comprising them, their combinations with second drug substances and the use thereof and the like. The compounds are protein kinase inhibitors and can be used for the treatment of diseases mediated by protein kinase inhibitors, e.g. for the treatment of various proliferative diseases.
Owner:NOVARTIS AG
Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor
ActiveUS9670213B2Inhibiting growth and proliferation and differentiationStrong inhibitory activityOrganic chemistryAntipyreticPteridine synthesisMedicinal chemistry
Owner:SHANGHAI YIDIAN PHARM TECH DEV CO LTD
Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.
Owner:SEAGEN INC
Pharmaceutical composition containing homoharringtonine and application of pharmaceutical composition
ActiveCN112704679AAntineoplastic agentsHeterocyclic compound active ingredientsHomoharringtonineMidostaurin
The invention belongs to the technical field of biological medicines, and relates to a pharmaceutical composition containing homoharringtonine (HHT) and an application of the pharmaceutical composition, in particular to the pharmaceutical composition containing the homoharringtonine and an application of the pharmaceutical composition to preparation of a medicine for treating leukemia. The invention particularly relates to an application of a pharmaceutical composition of HHT and a Bcl-2 inhibitor Venetoclax to treatment of AML or an application of the pharmaceutical composition of HHT and an FLT3 inhibitor (midostaurin, sorafenib, gilteritinib, crenolanib or quizartinib) to preparation of a medicine for treating AML of FLT3-ITD mutation. The molar ratio of the homoharringtonine to the venetoclax serving as the Bcl-2 inhibitor ranges from (1: 5) to (4: 1), and the molar ratio of the homoharringtonine to the FLT3-ITD ranges from (1: 5) to (5: 1). The components of the composition can be used at the same time or in any sequence.
Owner:SHENYANG PHARMA UNIVERSITY
5-position ring substituted 2, 4-diaminopyrimidine compound with phenylglycinol structure, preparation and application thereof
ActiveCN109206375AHas tyrosine kinase FLT3 inhibitory activityHas inhibitory activityOrganic active ingredientsOrganic chemistryDiaminopyrimidineOrganic chemistry
The invention discloses a 5-position ring substituted 2, 4-diaminopyrimidine compound with phenylglycinol structure, preparation and application thereof. The structure of the compound provided by theinvention is shown as general formula I, and the definitions of all substituent groups are described as the specification and claims. The compound shows remarkable inhibitory activity on Tel-BaF3-FLT3and BaF3-FLT3-ITD mutant cells, shows weak activity on Tel-BaF3-cKIT cells, and has good selectivity, thus being a very potential FLT3 inhibitor.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
4-(saturated aliphatic ring-pyrimidine/pyridine substituted)amino-1H-3-pyrazol carboxamide FMS-like tyrosine kinase 3 (FLT3) inhibitor and application thereof
ActiveCN109970717AStrong inhibitory activityOrganic active ingredientsOrganic chemistryFms-Like Tyrosine Kinase 3Pyridine
The invention relates to 4-(saturated aliphatic ring-pyrimidine / pyridine substituted)amino-1H-3-pyrazol carboxamide FMS-like tyrosine kinase 3 (FLT3) inhibitor, an application thereof, or pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug of the FLT3 inhibitor, a preparation method of the pharmaceutically acceptable salt, solvate, isomer, ester, acid, metaboliteor prodrug of the FLT3 inhibitor, a pharmaceutical composition comprising the compound, and a medical uses of the compounds and medical composition.
Owner:CHINA PHARM UNIV
Application of erlotinib in preparation of FLT3 inhibitor-type medicine
InactiveCN110063957AEnhanced inhibitory effectGood for inhibiting leukemiaOrganic active ingredientsSenses disorderSide effectErlotinib
The invention discloses application of erlotinib in preparation of an FLT3 inhibitor-type medicine and further discloses application of erlotinib in preparation of a medicine for treating leukemia. The erlotinib can inhibit the enzyme activity of FLT3, has an extremely-high inhibition function on FLT3-ITD mutant-type leukemia cells, has a good function of inhibiting leukemia in vivo, can have an inhibition function under the condition of a low side effect and is good in clinical application prospect.
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
FLT3 inhibitors for improving pain treatments by opioids
InactiveCN111093640ASmall doseMaintain Pain EfficacyNervous disorderImmunoglobulins against cell receptors/antigens/surface-determinantsOpioidergicTolerability
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
4-(aromatic heterocycle substituted) amino-1h-3-pyrazole carboxamide flt3 inhibitors and uses thereof
ActiveCN107245073BGood choiceStrong inhibitory activityOrganic active ingredientsOrganic chemistryMetabolitePharmaceutical medicine
Owner:CHINA PHARM UNIV
Synthesis, pharmacology and use of new and selective fms-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
Owner:UNIV REGENSBURG +1
CDK4-FLT3 inhibitor and application thereof
InactiveCN111377921AGood pharmacodynamics in vivoGood tumor treatmentOrganic active ingredientsOrganic chemistryCancer preventionMetabolite
The invention discloses a CDK4-FLT3 inhibitor and an application of the CDK4-FLT3 inhibitor. The compound is a compound shown as a formula I, and pharmaceutically acceptable salt, hydrate, solvate, metabolite, stereoisomer, tautomer or prodrug thereof. The compound can be used for preparing medicines for treating and / or preventing cancers.
Owner:武汉光谷通用名药物研究院有限公司
Pharmaceutical composition containing FLT3 inhibitor and chemotherapeutic agent for treating acute myelogenous leukemia
PendingCN114650823AEfficient combinationGood treatment effectOrganic active ingredientsAntineoplastic agentsTyrosine-kinase inhibitorPharmaceutical drug
Provided are pharmaceutical compositions for the treatment of acute myelogenous leukemia (AML); and a method for treating acute myelogenous leukemia by using the pharmaceutical composition. The pharmaceutical composition comprises a therapeutically effective combination of: an Fms-like tyrosine kinase-3 (FLT3) inhibitor, or a pharmaceutically acceptable salt or solvate thereof; and a chemotherapeutic agent or a pharmaceutically acceptable salt or solvate thereof.
Owner:HANMI PHARMA
Pharmaceutical composition of arsenic trioxide and FLT3 inhibitor and application of pharmaceutical composition
The invention belongs to the technical field of biological medicines, and relates to a pharmaceutical composition containing arsenic trioxide (ATO) and an application thereof, in particular to a pharmaceutical composition containing arsenic trioxide and an FLT3 inhibitor and an application of the pharmaceutical composition in preparation of medicines for treating leukemia, in particular to the application of a pharmaceutical composition of arsenic trioxide and an FLT3 inhibitor (midostaurin), sorafenib, gilteritinib, crenolanib or quizartinib in preparation of a medicine for treating AML withFLT3-ITD mutation. Wherein the molar ratio of arsenic trioxide to perindopril to sorafenib to gilteritinib is 100: 1-5: 1, the molar ratio of arsenic trioxide to crenolanib is 100: 1-5: 1, and the molar ratio of arsenic trioxide to quizartinib is 1000: 1-50: 1. The composition disclosed by the invention can selectively induce apoptosis of AML cells subjected to FLT3-ITD mutation, and can be used for treating leukemia.
Owner:SHENYANG PHARMA UNIVERSITY
Pteridinone derivatives and applications as flt3 inhibitors
ActiveCN107151249BNew structureStrong inhibitory activityOrganic active ingredientsSenses disorderDiseasePteridinones
Owner:EAST CHINA UNIV OF SCI & TECH
Use of flt3 car-t cells and flt3 inhibitors to treat acute myeloid leukemia
InactiveUS20200206266A1Increasing in recognition and eliminationHigh expressionOrganic active ingredientsMammal material medical ingredientsTyrosineOncology
The invention generally relates to the treatment of cancer with FLT3 targeting agents and kinase inhibitors. In particular, the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia (AML) with chimeric antigen receptor (CAR)-modified T cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3 inhibitors.
Owner:JULIUS MAXIMILIANS UNIV WURZBURG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com